Ipsen’s Dysport® approved for use in aesthetic medicine in Canada to be marketed by Medicis Aesthetics Canada

  Ipsen’s Dysport® approved for use in aesthetic medicine in Canada to be
  marketed by Medicis Aesthetics Canada

                       • Launch expected in April 2013

Business Wire

PARIS & MONTREAL -- April 09, 2013

Regulatory News:

Ipsen (Paris:IPN) (Euronext: IPN, ADR: IPSEY) today announced that Health
Canada has granted a marketing authorization for Dysport^® (Botulinum toxin
type A for injection) for the temporary improvement in the appearance of
moderate to severe frown lines (glabellar lines) in adult patients younger
than 65 years of age. Medicis Aesthetics Canada, a division of Valeant
Pharmaceuticals, will market Dysport^® for use in aesthetic medicine in
Canada. Launch is expected in April 2013.

Pierre Boulud, Executive Vice-President, Corporate Strategy, Ipsen’s group,
stated: “This presentation is in line with Ipsen’s commitment to an increased
focus and investment behind Dysport® and to extend its geographical footprint.
After its approval in 2009 in the United States, Dysport^® will now be
available in Canada for the treatment of glabellar lines.”

About Dysport®

The active substance in Dysport^® is a botulinum neurotoxin type A complex
which acts at the level of the neuromuscular junction in the targeted muscle
to block acetylcholine secretion, thereby reducing muscular spasm. It was
initially developed to treat motor disorders and various forms of muscular
spasticity, including cervical dystonia (or spasmodic torticollis, a chronic
condition in which the neck is twisted or deviated), spasticity of the
upper/lower part of the body in adults after a stroke, dynamic equinus foot
deformity in children with cerebral palsy, blepharospasm (involuntary
contraction of the eyelids) and hemifacial spasm (involuntary contraction of
the muscles located on one side of the face). Dysport^® was later developed
for the treatment of a wide variety of neuromuscular disorders, as well as for
use in aesthetic medicine. On 31 December 2012, Dysport^® had marketing
authorizations in force in 75 countries. In Canada, Dysport^® has been
approved for the temporary improvement in the appearance of moderate to severe
frown lines (glabellar lines) in adult patients younger than 65 years of age
since June 12^th, 2012.

About the agreement with Valeant

In March 2006, the Ipsen Group signed an agreement with the Medicis Group
(USA) granting the latter the exclusive right to develop, sell and market
certain formulations of botulinum toxin type A for use in aesthetic medicine
indications approved in the United States and Canada. On December 11^th, 2012,
Medicis was acquired by Valeant, who has succeeded Medicis in its rights of
Dysport^® in North America.

About Ipsen

Ipsen is a global specialty-driven pharmaceutical company with total sales
exceeding €1.2 billion in 2012. Ipsen’s ambition is to become a leader in
specialty healthcare solutions for targeted debilitating diseases. Its
development strategy is supported by three franchises: neurology,
endocrinology and uro-oncology. Moreover, the Group has an active policy of
partnerships.Ipsen'sR&D is focused onitsinnovative and differentiated
technological platforms, peptides and toxins. In 2012, R&D expenditure totaled
close to €250 million, representing more than 20% of Group sales. The Group
has close to 4,900 employees worldwide. Ipsen’s shares are traded on segment A
of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to
the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120
index. Ipsen has implemented a Sponsored Level I American Depositary Receipt
(ADR) program, which trade on the over-the-counter market in the United States
under the symbol IPSEY. For more information on Ipsen, visitwww.ipsen.com.

About Valeant Canada

Committed to Canada

As part of one of the world’s fastest growing international pharmaceutical
companies, Valeant Canada is committed to bringing quality products to
Canadians that benefit their wellbeing.

Our commitment to patient health can be felt in pharmacies, healthcare
practices and hospitals across the country, as Valeant Canada manufactures,
markets and distributes a wide selection of pharmaceutical products. A strong
commercial infrastructure enables us to provide new, cutting-edge, effective
pharmaceutical and consumer products to Canadians.

While we are proud to offer Canadians a wide range of quality products, we are
equally proud to have the best employees working for us across the country,
and at global headquarters in Montreal.

Committed to bringing quality products to you

Valeant Canada has a diverse product portfolio in several therapeutic areas,
including Pain Management, Cardiovascular Disease, Neurology and Dermatology,
and we continue to expand these areas with new offerings. And, as leaders in
new research and development in dermatology, Valeant Canada is also excited to
have established an R&D center of excellence for consumer dermatology in
Laval, Quebec.

Ipsen Forward Looking Statement

The forward-looking statements, objectives and targets contained herein are
based on the Group’s management strategy, current views and assumptions. Such
statements involve known and unknown risks and uncertainties that may cause
actual results, performance or events to differ materially from those
anticipated herein. All of the above risks could affect the Group’s future
ability to achieve its financial targets, which were set assuming reasonable
macroeconomic conditions based on the information available today.

Moreover, the targets described in this document were prepared without taking
into account external growth assumptions and potential future acquisitions,
which may alter these parameters. These objectives are based on data and
assumptions regarded as reasonable by the Group. These targets depend on
conditions or facts likely to happen in the future, and not exclusively on
historical data. Actual results may depart significantly from these targets
given the occurrence of certain risks and uncertainties, notably the fact that
a promising product in early development phase or clinical trial may end up
never being launched on the market or reaching its commercial targets, notably
for regulatory or competition reasons. The Group must face or might face
competition from Generics that might translate into a loss of market share.

Furthermore, the Research and Development process involves several stages each
of which involves the substantial risk that the Group may fail to achieve its
objectives and be forced to abandon its efforts with regards to a product in
which it has invested significant sums. Therefore, the Group cannot be certain
that favorable results obtained during pre-clinical trials will be confirmed
subsequently during clinical trials, or that the results of clinical trials
will be sufficient to demonstrate the safe and effective nature of the product
concerned. The Group also depends on third parties to develop and market some
of its products which could potentially generate substantial royalties; these
partners could behave in such ways which could cause damage to the Group’s
activities and financial results. The Group cannot be certain that its
partners will fulfill their obligations. It might be unable to obtain any
benefit from those agreements. A default by any of the Group’s partners could
generate lower revenues than expected. Such situations could have a negative
impact on the Group’s business, financial position or performance.

The Group expressly disclaims any obligation or undertaking to update or
revise any forward looking statements, targets or estimates contained in this
press release to reflect any change in events, conditions, assumptions or
circumstances on which any such statements are based, unless so required by
applicable law.

The Group’s business is subject to the risk factors outlined in its
registration documents filed with the French Autorité des Marchés Financiers.


For further information:
Didier Véron
Vice President, Public Affairs and Corporate Communications
Tel.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58
E-mail: didier.veron@ipsen.com
Brigitte Le Guennec
Media and Public Relations Officer
Tel.: +33 (0)1 58 33 51 17
Fax: +33 (0)1 58 33 50 58
E-mail : brigitte.le.guennec@ipsen.com
Financial Community
Pierre Kemula
Vice President, Corporate Finance, Treasury and Financial Markets
Tel.: +33 (0)1 58 33 60 08
Fax: +33 (0)1 58 33 50 63
E-mail: pierre.kemula@ipsen.com
Stéphane Durant des Aulnois
Investor Relations Manager
Tel.: +33 (0)1 58 33 60 09
Fax: +33 (0)1 58 33 50 63
E-mail: stephane.durant.des.aulnois@ipsen.com
Medicis Aesthetics Canada, A division of Valeant
Sarah McConnell, Account Manager
Strategic Objectives
416-366-7735 x 290 (toll-free 866-366-7733 x 290)
Rebecca Crittenden, Account Director
Strategic Objectives
416-366-7735 x 268 (toll-free 866-366-7733 x 268)
Press spacebar to pause and continue. Press esc to stop.